By Thomas Dobrow
Zimmer Biomet Holdings (NYSE:ZBH) has earned a consensus rating of “Buy” from the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $129.46.
Shares of Zimmer Biomet Holdings (NYSE:ZBH) traded up 0.11% during midday trading on Wednesday, hitting $100.08. 142,291 shares of the stock traded hands. The firm’s 50 day moving average price is $102.97 and its 200 day moving average price is $110.95. The company has a market capitalization of $20.35 billion and a PE ratio of 50.80. Zimmer Biomet Holdings has a 12-month low of $94.73 and a 12-month high of $121.84.